Servatus has two platforms: Modified Protein for the treatment of autoimmune diseases, and Microbial Biotherapeutics for the treatment of inflammatory conditions and bacterial infections.
The treatment of autoimmune diseases, such as rheumatoid arthritis and psoriasis, remains a major medical challenge, with current medicines unable to satisfactorily treat a large number of autoimmune diseases and often generating unpleasant side effects.
Servatus is engineering recombinant proteins to improve their clinical utility and boost their potential to provide more-effective treatment of autoimmune diseases, with minimal side effects.
In parallel, in one of the most exciting areas of global drug development, Servatus is developing live biotherapeutics for the treatment of microbiome-associated conditions, such as Inflammatory Bowel Disease (ulcerative colitis) and gastrointestinal conditions (C.diff infection and H.pylori infection).
Research and intellectual property
Servatus has completed preliminary research work on both the Modified Protein and Microbial Biotherapeutics and is proceeding with advanced pre-clinical work ahead of anticipated clinical trials.
Servatus’ core intellectual property and patents include a patent on “the directed alteration for improving clinical performance of selected protein drugs”. The company holds other patents for various microbial biotherapeutics, including for the treatment of wound infections, respiratory infections, inflammatory conditions, and conditions of the gastrointestinal tract.
Servatus’ goal is to commercialise its proprietary technology and engage with one or more corporate partners in the biopharmaceutical industry.